Home » Stocks » Spero Therapeutics

Spero Therapeutics, Inc. (SPRO)

Stock Price: $13.79 USD 0.42 (3.14%)
Updated Jul 6, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 284.01M
Revenue (ttm) 12.13M
Net Income (ttm) -79.11M
Shares Out 20.60M
EPS (ttm) -4.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 6, 2020
Last Price $13.79
Previous Close $13.37
Change ($) 0.42
Change (%) 3.14%
Day's Open 13.80
Day's Range 13.51 - 14.00
Day's Volume 95,812
52-Week Range 5.25 - 14.48

More Stats

Market Cap 284.01M
Enterprise Value 200.62M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 20.60M
Float 14.38M
EPS (basic) -4.25
EPS (diluted) -4.25
FCF / Share -3.21
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 623,223
Short Ratio 3.48
Short % of Float 3.80%
Beta 1.96
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 23.41
PB Ratio 3.35
Revenue 12.13M
Operating Income -80.34M
Net Income -79.11M
Free Cash Flow -62.74M
Net Cash 83.39M
Net Cash / Share 4.05
Gross Margin -392.65%
Operating Margin -662.33%
Profit Margin -652.20%
FCF Margin -517.21%
ROA -42.82%
ROE -80.83%
ROIC -168.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 0
Hold 0
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$20.60*
(49.38% upside)
Low
7.00
Current: 13.79
High
28.00
Target: 20.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue18.153.971.980.34-
Revenue Growth357.56%100.4%490.75%--
Gross Profit18.153.971.980.34-
Operating Income-63.22-42.81-41.73-33.22-13.33
Net Income-60.93-41.66-38.74-25.49-13.15
Shares Outstanding18.1616.002.590.310.25
Earnings Per Share-3.35-2.60-17.82-95.87-53.11
Operating Cash Flow-50.02-39.63-39.11-28.96-9.61
Capital Expenditures-0.31-2.44-0.03-0.83-0.23
Free Cash Flow-50.33-42.06-39.14-29.79-9.84
Cash & Equivalents82.0511587.5410.575.89
Total Debt5.55----
Net Cash / Debt76.5011587.5410.575.89
Assets10612993.4813.777.18
Liabilities31.5313.158.527.417.43
Book Value74.5711684.60-45.44-18.10
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Spero Therapeutics, Inc.
Country United States
Employees 57
CEO Ankit A. Mahadevia

Stock Information

Ticker Symbol SPRO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SPRO
IPO Date November 2, 2017

Description

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.